FDA says telehealth seller MEDVi misbranded compounded semaglutide and tirzepatide by implying MEDVi makes them and that they are FDA-approved.
What happened
FDA reviewed the website medvi.io in December 2025 and found it offers compounded semaglutide and tirzepatide drug products (compounded means mixed or made to order rather than made by the original brand manufacturer). The product labels pictured on the site name "MEDVi," which suggests MEDVi is the compounder when FDA says it is not. The site also said the products have the "same active ingredient" as Wegovy, Ozempic, Mounjaro and Zepbound, which FDA says implies the products are FDA-approved when compounded drugs are not.
What FDA found
The website pictures product labels bearing the name MEDVi, which tells buyers MEDVi made the drug when it did not, so the labeling is false or misleading.
FDCA § 502(a) [21 U.S.C. § 352(a)]; 21 CFR § 201.1(h)(2)Saying the products have the "same active ingredient as Wegovy and Ozempic" is misleading because it hints the products were FDA-approved or checked for safety and effectiveness, which they were not.
FDCA §§ 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]Saying the products have the "same active ingredient as Mounjaro and Zepbound" is misleading for the same reason: it implies FDA approval that compounded drugs do not have.
FDCA §§ 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]Shipping these misbranded drugs across state lines is a prohibited act.
FDCA § 301(a) [21 U.S.C. § 331(a)]Receiving or delivering misbranded drugs in interstate commerce is also prohibited.
FDCA § 301(c) [21 U.S.C. § 331(c)]A compounded drug only escapes the new drug approval requirement if it meets the conditions in section 503A or 503B, and the company must make sure it does.
FDCA §§ 503A, 503B [21 U.S.C. §§ 353a, 353b]
What FDA wants
FDA tells MEDVi to respond in writing within 15 working days to the Office of Compounding Quality and Compliance, describing the steps taken to fix the violations and prevent them from recurring. The response should name the entities that actually make the compounded products, include a representative sample of the product labeling, and either justify or show removal of the other website claims FDA may find misleading.
Who should pay attention
- telehealth and online platforms that market compounded GLP-1 drugs
- compounding pharmacies whose products are sold under someone else's name
- marketing and regulatory reviewers who approve website copy and product images for drug sellers
This is a summary. Read the original letter on fda.gov.